Skip to main content

13 May 2022

Meet TESSA: a new standard in viral vector manufacturing

OXGENE

Sponsored/Nature Communications /13 May 2022

View More

Abstract

A new transfection-free helper system supports a high-yield manufacturing process for recombinant adeno-associated viruses (rAAV), raising the bar for producing safe, high-quality viral vectors at scale.

To learn more about TESSA, evaluate it or discuss partnering to explore this technology with OXGENE, a WuXi Advanced Therapies Company, the advanced therapies business unit of WuXi AppTec, please visit OXGENE.com/TESSA.

The TESSA paper can be found here.

View the paper in full here.
×